| Summary: | 碩士 === 長榮大學 === 高階管理碩士在職專班 === 98 === Pharmaceutical industry was emerging in the nearest century, and was listed in the program of “Two Trillion, Two Star” in Taiwan. Since the product development and marketing pattern was different from other industry , and the market supply and demand were less influenced by economic cycle. In particular, the market demand would contrarily increase under the circumstances of influenza period and the social structure of aging population. Since the official launch of the National Health Insurance (NHI) on March 1st 1995, it emphasized the governmental focus on national’s health and medical treatment. NHI policy and development of pharmaceutical industry was closely related, therefore the direction of innovation and development of pharmaceutical industry was a worth-discussing topic.
The main purpose of this research was to organize an innovative scale through foreign-capital-based pharmaceutical organizations, to evaluate the development of organizational innovation in pharmaceutical industry. Such scale was helpful for measuring the innovative ability of organization in pharmaceutical industry, and serving as the base for innovation management and marketing strategy.
This research adopted the “measuring scale or organizational innovation on foreign-capital-based pharmacy manufacturers” to discuss with the top management team members from 12 foreign-capital-based pharmacy manufacturers, to discuss four main dimensions: product innovation, market opportunity, organizational structure and marketing strategies, and other 12 sub-dimensions. Through AHP (analytic hierarchy process), this research determined the relative weights of each dimension: Product innovation (0.373), market opportunity (0.162), organizational structure (0.203) and marketing strategy (0.262). base on the analysis of the results on organizational innovation performance four suggestions were given as a reference:
1.The initial focus of industrial chain developing strategy for foreign-capital-based manufacturers in Taiwan was organizational innovation performance.
2. Innovation and promotion of biotechnology industry would create a new product value.
3. Aggressive promotion of CRM (customer relationship management) system, to improve industrial competency.
4. Loosen relative regulations, to facilitate the promotion and marketing of industrial network.
The research purpose was to construct the dimension and evaluation index of organization innovation for foreign-capital-based manufacturers, to further realize the innovative ability and quality of foreign-capital-based manufacturers. The results were appropriate as reference of organizational innovation for pharmaceutical manufacturers.
|
|---|
